GlassScriptPhysician profile
James L Millen
NPI 1558373043
$902.31
in general payments reported to CMS, 2019-2025
23 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2021: $45.06 · 2022: $201 · 2023: $33.78 · 2024: $158 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $186.98 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $114.76 | 2022-2024 | |
| Lilly USA, LLC | $76.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $71.86 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $68.19 | 2019-2025 | |
| Madrigal Pharmaceuticals | $42.94 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $40.86 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $33.73 | 2024 | Minimed 780g |
| Dexcom, INC. | $31.96 | 2019-2021 | |
| Boston Scientific Corporation | $23.89 | 2019 | |
| Abiomed | $23.23 | 2024 | Impella |
| Kyowa Kirin, INC. | $23.04 | 2024 | Crysvita |
| Corcept Therapeutics | $22.56 | 2022 | |
| Shire North American Group INC | $17.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.23 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.93 | 2021 | |
| Cequr Corporation | $15.50 | 2022 | |
| Becton, Dickinson and Company | $15.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.82 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.33 | 2022 | |
| Merck Sharp & Dohme LLC | $12.47 | 2019 | |
| Medtronic Minimed, INC. | $11.65 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.01 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Millen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.